Hepatic Imaging
±, hepatic stiffness, hepatic steatosis, fibrosis
FIBROSIS, EVENT, HEPATIC STEATOSIS, HOFH
The baseline characteristics of 34 HoFH patients from the Italian cohort are reported in Table Baseline characteristics of a real‐world cohort of HoFH patients from ItalyAbbreviations: BMI, body mass index; HDL‐C, high‐density lipoprotein cholesterol; IQR, interquartile range; LDL‐C, low‐density lipoprotein cholesterol; MACE, major adverse cardiovascular event; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor; TC, total cholesterol; TG, triglycerides.Ultrasound and transient elastography were used to evaluate hepatic steatosis and hepatic stiffness (fibrosis), respectively. Of the total cohort (Change in ultrasound data in the Italian cohort (
In patients with elastography data at last follow‐up visit (n = 21), hepatic stiffness was normal in all patients treated with lomitapide for up to 117.4 months (9.8 years) with a mean of 4.9 ± 0.9 kPa (Figure Hepatic stiffness according to liver elastography by months of exposure to lomitapide in patients with follow‐up elastography data (